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Tumor macrophages are generally considered to be alternatively/M2 activated to induce
secretion of pro-angiogenic factors such as VEGF and MMPs. EMMPRIN (CD147, basigin)
is overexpressed in many tumor types, and has been shown to induce fibroblasts
and endothelial cell expression of MMPs and VEGF. We first show that tumor cell
interactions with macrophages resulted in increased expression of EMMPRIN and
induction of MMP-9 and VEGF. Human A498 renal carcinoma or MCF-7 breast carcinoma
cell lines were co-cultured with the U937 monocytic-like cell line in the presence of
TNFα (1 ng/ml). Membranal EMMPRIN expression was increased in the co-cultures
(by 3–4-folds, p < 0.01), as was the secretion of MMP-9 and VEGF (by 2–5-folds for
both MMP-9 and VEGF, p < 0.01), relative to the single cultures with TNFα. Investigating
the regulatory mechanisms, we show that EMMPRIN was post-translationally regulated
by miR-146a, as no change was observed in the tumoral expression of EMMPRIN
mRNA during co-culture, expression of miR-146a was increased and its neutralization
by its antagomir inhibited EMMPRIN expression. The secretion of EMMPRIN was also
enhanced (by 2–3-folds, p < 0.05, only in the A498 co-culture) via shedding off of the
membranal protein by a serine protease that is yet to be identified, as demonstrated by
the use of wide range protease inhibitors. Finally, soluble EMMPRIN enhanced monocytic
secretion of MMP-9 and VEGF, as inhibition of its expression levels by neutralizing
anti-EMMPRIN or siRNA in the tumor cells lead to subsequent decreased induction
of these two pro-angiogenic proteins. These results reveal a mechanism whereby
tumor cell-macrophage interactions promote angiogenesis via an EMMPRIN-mediated
pathway.
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INTRODUCTION
Solid tumors include tumor and stroma cells, particularly infil-
trating macrophages, which may consist of up to half of the tumor
mass (Mantovani et al., 2002; Murdoch et al., 2004). Macrophages
can be activated to become effector killer cells (classically or M1
activated) or to be involved in wound healing and angiogene-
sis (alternatively or M2 activated) (Mosser and Edwards, 2008;
Gordon and Martinez, 2010). However, since we now realize that
macrophages are very plastic and can be activated in many addi-
tional modes according to the microenvironment, this dichotomy
is really a simplified way to describe their activation and
function.
The three main macrophage subsets that are recognized within
the tumoral context are tumor-associated macrophages (TAMs)
(Lewis and Murdoch, 2005), Tie2 expressing monocytes (TEMs)
(De Palma et al., 2007), and myeloid-derived suppressor cells
(MDSCs) (Serafini et al., 2006; Murdoch et al., 2008), all of which
secrete varying amounts of pro-angiogenic factors (e.g., vascular
endothelial growth factor-VEGF), anti-inflammatory mediators
(e.g., TGF-β, IL-10, IL-13, PGE2) that inhibit the tumorici-
dal activity of immune cells (Mantovani et al., 2004; Murdoch
et al., 2005), and enzymes that degrade the extracellular matrix
(ECM) and make room for the growing tumor mass (e.g., matrix
metalloproteinases-MMPs). MMPs and VEGF are both crucial
for tumor progression, invasiveness, metastasis and angiogenesis
(Egeblad and Werb, 2002). High amounts of MMPs, particularly
MMP-9, degrade the ECM, release and activate VEGF, and allow
migration of cells (including infiltration of leukocytes, spread-
ing of metastatic tumor cells, and integration of pericytes and
endothelial cells into the tumor vasculature) (Murdoch et al.,
2008). VEGF is an extremely potent pro-angiogenic factor, a
chemoattractant for macrophages, and a regulator of MMP-
9 (Owen et al., 2003). Thus, a regulatory positive loop exists,
where MMP-9 regulates VEGF bioavailability, and VEGF regu-
lates MMP-9 expression (Hollborn et al., 2007).
Thus, the tumoral microenvironment is rich in anti-
inflammatory mediators (e.g., IL-10, IL-13, TGFβ, PGE2) that
skew macrophages toward alternative/M2 patterns of activation,
while hypoxia immobilizes them at the site (Murdoch et al., 2004).
However, the microenvironment also consists of low levels of pro-
inflammatory cytokines (e.g., IL-1β, TNFα) which paradoxically
enhance tumor angiogenesis and proliferation (Balkwill, 2009).
TNFα in particular can be produced by the tumor cells not only
to enhance their proliferation, but also to promote invasiveness
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through its ability to induce macrophage MMP-9 (Hagemann
et al., 2004)
In many solid tumors, expression of VEGF andMMPs, includ-
ing MMP-9, is up-regulated by the extracellular matrix metallo-
proteinase inducer (EMMPRIN, also called basigin or CD147).
This is a multifunctional protein that is expressed on the sur-
face of both tumor and stroma cells, including macrophages (Yan
et al., 2005; Nabeshima et al., 2006), and through homophilic
EMMPRIN:EMMPRIN interactions between these two cell types
may induce the expression of both MMPs and VEGF and increase
angiogenesis (Tang et al., 2004, 2005; Yurchenko et al., 2010).
Other protein partners for EMMPRIN, such as cyclophilin A
and B, may also be responsible for its pro-angiogenic activity,
as well as for inducing chemotaxis and recruitment of leuko-
cytes to the tumor (Yurchenko et al., 2010). Overexpression of
EMMPRIN was found in many types of tumors, and was cor-
related to VEGF and MMP-9 induction and increased tumor
invasiveness (Zhou et al., 2005). Conversely, EMMPRIN neu-
tralizing antibody reduced VEGF and MMP-9 expression (Tang
et al., 2006) leading to reduced invasiveness. EMMPRIN may be
found as a transmembranal protein or in its secreted form, and
both forms can mediate its homophilic interactions (Belton et al.,
2008). In this study we show that EMMPRIN is up-regulated by
tumor cell-macrophage interactions and its proteolytic cleavage
is enhanced in co-culture, resulting in increased amounts of the
soluble form. Moreover, we show that the secreted form is suffi-
cient to induce both VEGF andMMP-9, and is pro-angiogenic by
itself.
METHODS AND MATERIALS
CELLS
The human renal carcinoma A498 (ATCC HTB-44), breast car-
cinoma MCF-7 (ATCC HTB-22) and U937 monocyte-like cells
(ATCC CRL-1593) were cultured in RPMI-1640 medium with
10% fetal calf serum (FCS), 1% L-glutamine and antibiotics. The
three cell lines were regularly tested for morphological changes
and presence of mycoplasma. In some experiments cells were
subjected to stimulation with TNFα (1 ng/ml, R&D systems,
Minneapolis, MN), incubated with anti-EMMPRIN (LEAF™
Purified anti-human CD147 Antibody, BioLegend, San Diego,
CA) or with recombinant EMMPRIN (R&D systems). To avoid
possible masking of signals by exogenous stimuli, 106 cells were
plated in 24-well plates in RPMI-1640 without FCS and TNFα
was added for 48 h. In all co-cultures, tumor cells and U937 cells
were plated at a 2:1 ratio. Cell viability was determined using the
XTT kit (Biological industries, Beit-Haemek, Israel). The human
endothelial cell line EaHy926 (gift of Dr. C. J. Edgell, University
of North Carolina, Chapel Hill, NC) was cultured in DMEM
with 2% glutamine, 10% FCS, 2% hypoxanthine-aminopterin-
thymidine (HAT), and 1% antibiotics.
ELISA
The human EMMPRIN, MMP-9 and VEGF ELISA kits were
performed according to the manufacturer’s instructions (R&D
systems). Samples were diluted 1:200 for determination of
EMMPRIN and MMP-9, and 1:100 for determination of VEGF,
according to previous calibration experiments.
FLOW CYTOMETRY
106 Cells were centrifuged and re-suspended in RPMI-1640 with
1% FCS, and then incubated with 1μg of Alexa 647-conjugated
anti-human CD147 or with its isotype control (BioLegend) for
30min at 4◦C. After washing, the cells were fixed in 0.1%
formaldehyde and analyzed by flow cytometer, (LSRII, BD
Biosciences, San Jose, CA). To distinguish between EMMPRIN
expression on U937 cells and on tumor cells, A498 and MCF-7
cells were first labeled with 1μMof Cell Tracker™Green CMFDA
(Life Technologies-InVitrogen, Darmstadt, Germany) according
to the manufacturer’s instructions, and only then were incu-
bated in the experimental conditions. Dead cells were excluded
from the analysis by their forward and sideway light-scattering
properties.
QUANTITATIVE REAL-TIME PCR
Total RNA was extracted from 106 U937, A498, or MCF-7
cells using the RNA extraction kit (Norgen biotek, Ontario,
Canada), and 500 ng were transcribed to cDNA using the High
Capacity cDNA Reverse Transcription kit (Applied Biosystems,
Foster City, CA). EMMPRIN mRNA expression and its refer-
ence gene GusB, or miR-146a and its reference gene U6 were
quantified by real-time PCR using the TaqMan assay on demand
kit with the StepOne system (Applied Biosystems). The com-
parative CT method was used for relative quantification,
and non-stimulated cells served as a calibrator in each experi-
ment, to allow comparison of relative quantity (RQ) between the
samples.
REVERSE TRANSFECTION AND INHIBITION OF MIR-146a OR EMMPRIN
EXPRESSION
The siPORT NeoFX transfection agent (Applied
Biosystems/Ambion, Austin, TX) was diluted 1:25 with OPTI-
MEM1 medium (Gibco, Invitrogen), combined with 30 nM
of the anti-miR-146a inhibitor™ or its Cy3-labeled negative
control (anti-miR-NC), or with 5 nM of EMMPRIN siRNA or
its negative control (all reagents from Ambion). Solutions were
incubated 10min to allow transfection complexes to form and
then dispensed into 24-well plates. 6 × 104 A498 or MCF-7
cells/well were overlaid in suspension over the transfection
complexes and gently tilted to evenly distribute the complexes.
Cells were incubated at 37◦C overnight, followed by replacement
with fresh medium and stimulation with TNFα for 48 h. These
conditions were calibrated according to the manufacturer’s
instructions, reaching transfection efficiency of >92%.
ISOLATION OF EXOSOMES
106 A498 or MCF-7 cells were incubated in single- or co-
cultures with 0.5 × 106 U937 cells in the presence of TNFα
(1 ng/ml), supernatants were collected and centrifuged at 800 g
for 10min and then at 12,000 g for 30min to sediment sus-
pended cells. The resulting supernatants were ultra-centrifuged
at 110,000 g (Micro-Ultracentrifuge RCM150, rotor S120AT2-
0200; Thermo Scientific, Sorvall, Suwanee, GA, USA) for 1.5 h
at 4◦C to pellet the exosomes. Both pellets and supernatants
were evaluated for the presence of EMMPRIN protein by
ELISA.
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In vitro “WOUND ASSAY”
EaHy926 monolayers (1 × 106 cells) in 24-well dishes were
wounded with a wooden toothpick after overnight incubation,
and the line of injury was marked. Detached cells were washed
away with medium, and cells were incubated with or without
human recombinant EMMPRIN (200 ng/ml) or with 100μl of
supernatants (diluted 1:4 with medium) derived from the siRNA
experiments. Images of the field of injury were acquired at the
beginning of the experiment and after 48 h. In each experiment,
average distances between the two sides of the wound were mea-
sured in different locations along the wound (at least 10 locations
per field), in day 0 and in day 2, and analyzed with ImagePro plus
4.5 software. The percent change was then calculated relative to
day 0.
In vivo PLUG ASSAY
Liquid Matrigel (0.4ml) was mixed with 200 ng/ml of human
recombinant EMMPRIN and injected subcutaneously into the
flank of BALB/c mice. As a control, Matrigel was mixed with
serum-free DMEM and injected as above. Matrigel plugs were
surgically removed after 7 days and photographed to give visual
assessment of angiogenesis. All animal studies were approved by
the Animal Care Committee of the Technion.
STATISTICAL ANALYSES
All values are presented as means ± SE. Significance between
two groups was determined using two-tailed unpaired t-test.
Differences between three ormore experimental groups were ana-
lyzed using analysis of variance (ANOVA) and the Bonferroni’s
multiple comparison tests. P-values exceeding 0.05 were not
considered significant.
RESULTS
CO-CULTURE INCREASES THE EXPRESSIONOF EMMPRIN,
MMP-9 AND VEGF
Preliminary studies were performed to calibrate the in vitro sys-
tem. TNFα was added to each of the single cell cultures at
a concentration of 1 ng/ml, which is similar to the concentra-
tion found in the tumor microenvironment (Elamin et al., 2008;
Charles et al., 2009; Ali et al., 2012). At this concentration TNFα
was sufficient to induce MMP-9, but did not induce cell death,
as was estimated by the XTT assay (1.03 ± 0.04, 0.96 ± 0.02, and
0.99 ± 0.05 folds for A498, MCF-7, and U937 cells, respectively,
relative to each of the non-stimulated cells). Furthermore, incu-
bation time of 48 h was optimal to observe accumulation of VEGF
and MMP-9 in the supernatants. As macrophages may make up
as much as 50% of the tumor mass, tumor cells and monocytes
were incubated at a ratio of 2:1, as was demonstrated before (Blot
et al., 2003; Perske et al., 2010).
In all three cell lines examined separately or in co-culture, all
of the cells (99.6 ± 0.3%) expressed surface EMMPRIN, how-
ever, with different intensities. The U937 cells expressed low levels
of membranal EMMPRIN (Figures 1A,B), which increased by
4.5-folds during co-culture with both A498 and MCF-7 cells.
Likewise, expression of membranal EMMPRIN on the tumor
cells that was 2–3-fold higher in the single cultures than in
the U937 cells, was increased during co-culture (by 4-folds and
3-folds in the A498 and MCF-7 cells, respectively, p < 0.05
and p < 0.001 relative to the singe cultures). TNFα had no
effect on the membranal expression of EMMPRIN in all cell
types, during separate incubation or in co-cultures. In con-
trast, TNFα elevated the amounts of secreted EMMPRIN from
A498 cells cultured alone (by 2-folds, p < 0.05), but not from
MCF-7 cells, which already secreted high levels of EMMPRIN
(Figure 1B). Co-culture increased the accumulation of secreted
EMMPRIN in the A498 experiments (by 3-folds and 1.5-folds
relative to the U937 and A498 single cultures, respectively, p <
0.001, Figure 1C), although this increase was only additive. In
contrast, using the MCF-7 cells, the amounts of the secreted
EMMPRINwere not significantly different in the co-cultured cells
relative to the single MCF-7 culture, suggesting that this cell line
already secreted maximal amounts of EMMPRIN without further
stimulation.
In both tumor cell lines and in the monocytic cell line, pres-
ence of TNFα was necessary to induce MMP-9 secretion in each
of the single cultures, however, the co-cultures significantly ele-
vated this level, synergistically for the A498 cells (5-folds, p <
0.001) and additively for the MCF-7 cells (1.6-folds, p < 0.001,
Figure 1D). Similarly, co-cultures increased the accumulation of
secreted VEGF (Figure 1E). In the A498 cells, co-cultures syner-
gistically increased VEGF secretion (by 3-folds, p < 0.001 relative
to each of the single cultures), and addition of TNFα, which had
no effect in the single cultures, further stimulated secretion by
2-folds. In the MCF-7 cells, co-cultures increased the accumula-
tion of VEGF additively only in the presence of TNFα (by 2-folds,
p < 0.01 relative to each of the single cultures).
EMMPRIN EXPRESSION IS POST-TRANSCRIPTIONALLY REGULATED
BY MIR-146a
We next evaluated the expression of EMMPRIN at the RNA
levels. EMMPRIN has two known isoforms. The short isoform
has only two Ig-like domains, whereas the long isoform has 3
such domains. Preliminary experiments indicated that both iso-
forms are expressed in the three cell lines, however, the short
isoform was the prevalent one (average Ct values of 20 cycles),
whereas the long isoform was scarce (average Ct values of 31).
We, therefore, evaluated the effect of TNFα and co-culture on the
accumulation of EMMPRIN mRNA levels of the short isoform
only (Figure 2A). In order to estimate the level of EMMPRIN
mRNA in each cell type, co-cultured cells were incubated in sepa-
rate inserts (membrane of 0.3μm pore size), so as to preclude cell
migration between the two compartments. No significant change
was observed in the EMMPRIN mRNA levels in either A498 or
MCF-7 cells relative to each of the single cultures, whereas in the
U937 cells co-culturing with either A498 or MCF-7 cells reduced
these levels by 40 and 45% relative to the single culture (p < 0.05
and p < 0.01, respectively).
The discrepancy between the elevated protein levels observed
before and the unchanged or decreased levels of the mRNA sug-
gested a post-transcriptional regulation of EMMPRIN, which
could be mediated through microRNA. We chose to examine
the involvement of miR-146a that is a known inflammatory
microRNA and has been implicated in tumor-macrophage inter-
actions before (Perske et al., 2010). We could show (Figure 2B)
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FIGURE 1 | Continued
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FIGURE 1 | The effect of co-culture on the secretion of EMMPRIN, MMP-9
and VEGF. 106 A498 or MCF-7 cells were incubated in a serum-free medium
either separately or with 0.5× 106 U937 cells in co-culture for 48h, with or
without the addition of TNFα (1 ng/ml), and 0.5× 106 U937 cells were
incubated in a serum-free medium with or without the addition of TNFα
(1 ng/ml). (A) Representative dot plot for the A498 and U937 co-cultures.
Light blue and orange histograms—EMMPRIN expression in single cultures
of A498 cells and U937 cells, respectively; Blue and red
histograms—EMMPRIN expression measured separately on A498 or U937
cells, respectively, incubated in their co-cultures. Gray histogram—isotype
control. (B) Mean fluorescence (MF) of the membranal expression of
EMMPRIN that was evaluated by flow cytometry (n = 8). Concentrations of
secreted proteins were determined in the supernatants by ELISA for (C)
EMMPRIN (n = 6), (D) MMP-9 (n = 8) and (E) VEGF (n = 8).
that the expression of miR-146a was elevated by the co-culture
relative to each of the non-stimulated single cultures (by 146-
folds, ∼200-fold, and ∼300-folds for A498, MCF-7 and U937,
p < 0.05). As miR-146a is an inflammatory miRNA, TNFα
increased its levels, although not significantly (by 50-folds and
2.5-folds for A498 and U937 cells, respectively), and the co-
culture further increased it in the stimulated A498 and U937
cells (by 3-folds and 160-folds, p < 0.05), whereas in the MCF-
7 cells TNFα did not increase miR-146a expression relative to the
non-stimulated cells.
To show that this microRNA regulates the expression of
EMMPRIN, we next neutralized its activity by transfecting the
tumor cells with its antagomir anti-miR-146a and then co-
culturing themwith the U937monocytes in the presence of TNFα
(Figure 2C). This neutralization resulted in decreased levels of
secreted EMMPRIN protein, which did not reach significance
in the A498 cells (by 1.5-folds), but was significantly different
(3-folds, p < 0.01) for MCF-7 cells.
SOLUBLE EMMPRIN IS GENERATED BY A SERINE PROTEASE
The way that the secreted form of EMMPRIN is generated
remains controversial, where some evidences indicate secretion by
exosomes (Keller et al., 2009), and some demonstrate proteolytic
cleavage by MMPs (Tang et al., 2004). We investigated several
different possibilities for the generation of soluble EMMPRIN.
First, we explored whether the co-culture of the tumor cell
lines with the U937 monocytes induce alternative splicing of the
EMMPRIN mRNA, so that the transmembranal portion of the
molecule is deleted and the product cannot be anchored to the
membrane. We, therefore, amplified the extracellular and trans-
membranal regions of the short EMMPRIN mRNA (indicated in
Figure 3A) and quantified the transcript by both sets of primers.
No change was observed between the extracellular (short iso-
form) and transmembranal regions of the single- and co-cultures
of the A498 and MCF-7 cells (Figure 3B). Likewise, no such
change was observed for the U937 cells, despite the reduction
in the overall EMMPRIN transcript that was observed before
(Figure 2A).
Next, we evaluated the presence of EMMPRIN protein in exo-
somes, by precipitating the exosomes using ultracentrifugation,
an accepted method for exosome isolation (Lahat et al., 2011).
However, EMMPRIN was exclusively found in the supernatants
and was not sedimented at all after ultracentrifugation, indicating
that it is not found in exosomes (Figure 3C).
Finally, we explored the possibility of proteolytic cleavage of
the membranal EMMPRIN. To this end, we incubated the tumor
cell lines in co-cultures with U937 monocytes in the presence
of TNFα, to give rise to maximal secretion of EMMRPIN, and
with a wide range of protease inhibitors (Aprotinin, the serine
protease inhibitor; Leupeptin, the serine, cysteine and threonine
protease inhibitor; Pepstatin A, the aspartyl protease inhibitor;
Phenanthroline, the MMPs inhibitor), and with bafilomycin A1,
the lysosomal inhibitor which prevents lysosomal acidification.
These inhibitors collectively inhibit families of proteases with
potential access to membranal EMMPRIN either at the plasma
membrane or at the endosomal pathway. Different inhibitors
in optimal concentrations, which were determined to be inca-
pable of causing cell death in preliminary experiments (data
not shown), were added to the co-cultures and their effect
on the secretion of EMMPRIN was evaluated by ELISA. Each
value is presented as fold from control (the co-cultured cells
in the presence of TNFα) to allow better visualization of the
differences exerted by the inhibitors. In both A498 and MCF-
7 co-cultures with the monocytic U937 cell, only aprotinin
(Figure 3D) caused a significant decrease in secreted EMMPRIN
(a 14 and 46% reduction in A498 andMCF-7 co-cultures, respec-
tively, p < 0.001).
EMMPRIN IS REQUIRED FOR FULL INDUCTION OF VEGF AND MMP-9
VEGF and MMP-9 are essential for tumor angiogenesis, and can
be induced by a myriad of mediators found in tumor microen-
vironment, including hypoxia, TNFα or EMMPRIN. We used
three approaches to demonstrate that EMMPRIN is required for
maximal induction of both VEGF and MMP-9.
First, we incubated each of the cell lines, with or without
TNFα, with increasing amounts of recombinant EMMPRIN.
EMMPRIN alone had no significant effect on the secretion of
MMP-9 in all three cell lines (Figure 4), but in the presence of
TNFα the high amounts of the recombinant protein increased
the secretion of MMP-9 by 2.5-folds from the U937 cells (p <
0.001), by 4-folds from the A498 cells (p < 0.01) and by 3-
folds from the MCF-7 cells (p < 0.05), demonstrating a dose
response. The secretion of VEGF was not affected by the presence
of TNFα, and was significantly increased by the high amounts
of the recombinant protein only in the case of the U937 cells
(by 2-folds, p < 0.01). Since the recombinant EMMPRIN we
used is a chimeric product where the IgG Fc fragment is fused
to the carboxy-terminus of EMMPRIN, we made sure that this
fragment alone does not induce MMP-9 or VEGF secretion
from the cells (Figure 4) and used it as a control in all the
experiments.
Secondly, we incubated the TNFα-stimulated cells in co-
culture, and neutralized the effects of EMMPRIN by adding its
specific antibody (at 2 ng/ml), a concentration that was deter-
mined after preliminary calibration experiments. In A498 cells
co-cultured with U937 cells, anti-EMMPRIN reduced MMP-
9 secretion by 32% (p < 0.001) and VEGF secretion by 48%
(p < 0.05) (Figure 5). Likewise, in MCF-7 cells co-cultured with
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FIGURE 2 | EMMPRIN is regulated at the post-transcriptional level.
0.6× 105 A498 or MCF-7 cells were incubated in single- or co-cultures
with 0.3× 105 U937 cells in the presence of TNFα (1 ng/ml) for 48h. To
allow estimation of mRNA or miRNA levels in each cell type, co-cultured
cells were incubated in separate inserts (0.3μm pore size), thus
precluding cell migration between the two compartments. In some of
the wells cells were transfected with anti-miR-146a or anti-miR-NC
(scrambled negative control). Total RNA was extracted and transcribed to
cDNA. (A) Expression of the short EMMPRIN mRNA isoform was
determined by quantitative real-time PCR amplification (n = 4). (B) The
expression of miR-146a was determined in each of the single and
co-cultured cells cell lines (n = 3) (C) The effect of neutralization of
miR-146a in the tumor cell lines on the expression of EMMPRIN protein
in co-cultures was determined (n = 3).
U937 cells the antibody reduced MMP-9 secretion by 63% (p <
0.05) and VEGF secretion by 61% (p < 0.01). In the case ofMCF-
7, the antibody reduced the expression of bothMMP-9 and VEGF
to levels comparable to those induced by TNFα in the single cul-
tures, whereas in the A498 cells the antibody reduced MMP-9 and
VEGF levels only partially, andMMP-9 and VEGF levels were still
higher than those found in the TNFα-stimulated single cultures
(Figure 5).
Thirdly, we specifically reduced the expression of EMMPRIN
in the tumoral cells using EMMPRIN siRNA. To make sure that
EMMPRIN was maximally knocked down, we used two dif-
ferent siRNA sequences as well as their combination, and all
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FIGURE 3 | Possible mechanisms for generating secreted EMMPRIN
protein. 106 A498 or MCF-7 cells were incubated in single- or co-cultures
with 0.5× 106 U937 cells in the presence of TNFα (1 ng/ml) for 48h. (A) A
schematic representation of the different exons of the EMMPRIN mRNA. The
primers used for the amplification of the transmembranal (TM) or
extracellular regions of the short isoform are indicated by small arrows. (B)
Total RNA was extracted and transcribed into cDNA. Amplification of both the
extracellular and transmembranal regions by quantitative real-time PCR was
used to assess alternative splicing (n = 3). (C) Supernatants were collected
and ultra-centrifuged as described in the methods. Presence of the EMMRIN
protein in exosomes was determined by evaluating its concentrations in both
pellets and supernatants by ELISA (n = 4). (D) Ability of a wide range of
protease inhibitors (optimal concentrations indicated) to inhibit EMMPRIN
secretion was evaluated by ELISA (n = 5).
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FIGURE 4 | Effect of recombinant EMMPRIN on the secretion of MMP-9,
VEGF, and EMMPRIN. 5 × 105 A498, MCF-7 or U937 cells were incubated
separately in a serum-free medium with or without TNFα (1 ng/ml) for 48 h,
and with the addition of increasing amounts of recombinant EMMPRIN or the
IgG Fc fragment (at 200ng/ml). Concentrations of MMP-9 and VEGF were
determined in the supernatants using ELISA (n = 7).
three possibilities resulted in similar inhibition of EMMPRIN
protein production (about 5-folds for both A498 and MCF-7
cells, p < 0.05 and p < 0.01, respectively, Figure 6C). In A498
or MCF-7 co-cultures with the monocytic U937 cell line, the
absence of EMMPRIN resulted in inhibition of VEGF secretion
by 8–9-folds and 6–7-folds, respectively, (p < 0.05 and p < 0.01,
respectively, relative to the TNF-stimulated co-cultures without
knocking down EMMPRIN, Figure 6B). Likewise, in both A498
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FIGURE 5 | EMMPRIN neutralization inhibits secretion of VEGF and
MMP-9. 5 × 105 A498 or MCF-7 cells were incubated separately or in
co-cultures with 2.5× 105 U937 cells in a serum-free medium supplemented
with TNFα (1 ng/ml) for 48h, with or without the addition of anti-EMMPRIN
(2ng/ml). Concentrations of (A) MMP-9 and (B) VEGF were determined in
the supernatants using ELISA (n = 7).
andMCF-7 co-cultures, reduced EMMPRIN expression inhibited
secretion of MMP-9 by about 3-folds (p < 0.05, Figure 6A).
SOLUBLE EMMPRIN IS SUFFICIENT TO INDUCE MMP-9 AND VEGF
Although we have shown that EMMPRIN is required for the max-
imal induction of VEGF andMMP-9 in co-cultures of tumor cells
with monocytes, it remains unclear whether the effect is mediated
by the membranal or the soluble protein. The dose-dependent
effect of the recombinant EMMRPIN (Figure 4) was a first indi-
cation that the soluble protein mediates the effect. We further rea-
soned that soluble EMMPRIN found in the supernatant would be
sufficient to induce secretion of VEGF and MMP-9 in the oppo-
site cell type. We therefore, collected sups from TNFα-stimulated
single cultures of each of the tumor cells, and incubated them
diluted in medium at a ratio of 1:4 with U937 cells, with or
without the presence of TNFα (Figure 7). Relative to the TNFα-
stimulated U937 single culture, the A498- or MCF-7-derived sups
non-significantly increased MMP-9 secretion from U937 cells by
1.44- and 1.26-folds, respectively, but anti-EMMPRIN specifically
inhibited it by 3–4-folds (p < 0.05). Similarly, the A498- orMCF-
7-derived sups increased VEGF secretion from U937 cells by
2.5-folds (p < 0.01), and anti-EMMPRIN specifically inhibited
it by 2–3-folds (p < 0.05). In contrast, the reciprocal incubation
of U937-derived sups with both TNFα-stimulated tumor cells
(Figure 8) did not affect MMP-9 secretion, and elevated VEGF
secretion by about 2.5-folds (p < 0.001). However, this effect on
VEGF was not specific to EMMPRIN, as indicated by the lack of
response to anti-EMMPRIN.
To finally prove that soluble EMMPRIN can mediate MMP-
9 and VEGF induction in co-cultures, we incubated the two
cell types in Boyden-modified chambers, where the inserts
had a 0.3μm pore size that prevented cell–cell contact. As
before, the co-incubation of the A498 or the MCF-7 tumor
cells with the U937 monocytic cell line in a mixture that
allows cell–cell contact resulted in increase of both MMP-9
and VEGF in the supernatants, whereas the separate incu-
bation of the cells in the inserts did not change this effect
(Figure 9).
SOLUBLE EMMPRIN IS PRO-ANGIOGENIC
In addition to the ability of EMMPRIN to induce VEGF and
MMP-9, we asked if EMMPRIN has direct pro-angiogenic
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FIGURE 6 | Effect of EMMPRIN siRNA on the secretion of MMP-9, VEGF
and EMMPRIN. 0.6× 105 A498 or MCF-7 cells were incubated separately or
in co-cultures with 0.3× 106 U937 cells in a serum-free medium
supplemented with TNFα (1 ng/ml) for 48h. Tumor cells were first transfected
with 5nM of each of the two different EMMPRIN siRNA molecules, their
combination or the negative control (NC), or left untreated. Concentrations of
(A) MMP-9, (B) VEGF, and (C) EMMPRIN were determined in the
supernatants using ELISA (n = 5).
effect on endothelial cells. Since endothelial cells migrate as
one sheet, and migration and proliferation are inseparable,
the distances between the two sides of the wound and their
enhanced rate of closure over time reflect a pro-angiogenic activ-
ity. Figures 10A,B demonstrate that recombinant EMMPRIN
(200 ng/ml) increased migration/proliferation of EaHy926 cells
by 2.7-folds, although this trend did not reach significance.
In a complementary experiment (Figures 10C,D), supernatants
derived from A498 tumor cells that were transfected with
EMMPRIN siRNA demonstrated a 7-fold (p < 0.05) decreased
ability to repair the wound compared to untreated supernatants.
Similar results were observed for MCF-7-derived supernatants
(data not shown), suggesting a requirement for EMMPRIN
presence.
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FIGURE 7 | Effect of cancer cell supernatants on monocyte expression of
VEGF and MMP-9 is mediated through soluble EMMPRIN. 2 × 105 U937
cells were separately incubated in the presence of TNFα (1 ng/ml) for 48 h
with or without the addition of diluted (1:4) supernatants derived from A498 or
MCF-7 cells, and with the neutralizing anti-EMMPRIN antibody (2 ng/ml).
Concentrations of (A)MMP-9 and (B) VEGFwere determinedby ELISA (n = 5).
To evaluate the pro-angiogenic effects of EMMPRIN in vivo
we used the Matrigel plug assay, where liquefied Matrigel mixed
with medium or with recombinant EMMPRIN (200 ng/ml) was
injected subcutaneously. The plugs were harvested after 7 days
and their gross morphology is presented (Figure 10E). The con-
trol plugs are clear and transparent with almost no visible
blood vessels, whereas plugs that were mixed with recombinant
EMMPRIN are opaque, reddish and clearly show formation of
functional blood vessel network, strongly suggesting increased
angiogenesis.
DISCUSSION
EMMPRIN has been shown before to be pro-angiogenic, through
its ability to induce MMPs and VEGF. Here we demon-
strate some novel points: (a) Expression of EMMPRIN is
increased in tumor cells upon co-culturing with macrophages;
(b) EMMPRIN is post-transcriptionally regulated by miRNA-
146a; (c) Soluble EMMPRIN retains its biological activity, is
required for maximal induction of both VEGF and MMP-
9, and is generated by a serine protease that is yet to be
identified; (d) soluble EMMPRIN alone has a pro-angiogenic
activity and a direct effect on endothelial cells both in vitro and
in vivo.
Enhanced EMMPRIN expression has been described before in
many types of tumor tissues, but was usually not accompanied
by detection of EMMPRIN expression on stromal cells (Zhong
et al., 2008; Liang et al., 2009; Omi et al., 2012; Pinheiro et al.,
2012; Lu et al., 2013), suggesting that stromal cell expression of
EMMPRIN in vivo was very low and below the levels of antibody
detection. Studies in vitro demonstrated that tumor cells enhance
their expression of EMMPRIN when co-cultured with other cell
types, such as fibroblasts (Tang et al., 2004; Sato et al., 2009) or
endothelial cells (Caudroy et al., 2002; Bougaten et al., 2009), but
expression of EMMPRIN inmonocytes/macrophages co-cultured
with tumor cells was hardly investigated. Here we show that
EMMPRIN is constitutively expressed, although in low levels, on
both cell types. The interactions of monocytes with tumor cells
in co-cultures in vitro lead to increased membranal expression of
the EMMPRIN protein in both cell types, but mostly in the tumor
cells. Thus, in our system monocytes behave similarly to other
stromal cells, and it is the tumor cells that are mostly responsible
for the overexpression of EMMPRIN.
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FIGURE 8 | Effect of monocyte supernatants on cancer cell expression of
VEGF and MMP-9. 2 × 105 A498 or MCF-7 cells were separately incubated
in the presence of TNFα (1 ng/ml) for 48h with or without the addition of
diluted (1:4) supernatants derived from U937 cells, and with the neutralizing
anti-EMMPRIN antibody (2 ng/ml). Concentrations of (A) MMP-9 and (B)
VEGF were determined by ELISA (n = 5).
Themolecular mechanism responsible for this elevated expres-
sion of EMMPRIN in co-cultures remains unknown, although
EGFR and angiotensin II were implicated in its expression in
fibroblasts and macrophages, respectively (Weidle et al., 2010;
Yang et al., 2010), but not in tumor cells. We have shown that
EMMPRIN mRNA in the tumoral cell lines remains unchanged,
and has even decreased in the U937 cells, whereas the protein
expression was enhanced. This suggested post-transcriptional or
translational regulation, and placed microRNA as possible regu-
lators. We have chosen to look at miR-146a, as it plays a major
role in both inflammatory processes and in regulation of can-
cer (Baltimore et al., 2008), and was previously implicated in the
regulation of tumor cell-macrophage interactions (Perske et al.,
2010). We first demonstrated that miR-146a is increased both in
the two tumor cells and in the monocytic cells during co-culture,
and then that its neutralization specifically inhibited secretion of
EMMPRIN protein. These results further support a role for miR-
146a in the interactions between tumor cells and macrophages,
and suggest that increased miR-146a enhances, rather than
inhibits translation of EMMPRIN. This was unexpected, as
microRNAs usually inhibit protein translation. However, it is
possible that miR-146a could indirectly regulate another pro-
tein that either controls EMMPRIN translation or interacts with
EMMPRIN to enhance its degradation. Both possibilities may
result in enhanced EMMPRIN expression. Alternatively, since
different algorithms (e.g., miRanda, TargetScan) predict that
miR-146a can directly bind to EMMPRIN mRNA, it is possi-
ble that miR-146a cooperates with other microRNAs, resulting
in complex and non-linear effects. It is also noteworthy that
microRNAs do not always inhibit translation, and in viruses
they have been shown to regulate their enhanced replication, as
is the case for the liver-specific miR-122 and hepatitis C virus
(Jopling, 2008), suggesting an additional mode of action for
microRNAs. The question of which signal elevates the expres-
sion of miR-146a in co-culture in both cell types merits further
investigation.
In addition to the elevated membranal expression of
EMMPRIN, co-cultures also increase soluble EMMPRIN, partic-
ularly in the A498 and U937 co-cultures. Previous studies have
suggested three possible mechanisms that may generate solu-
ble EMMPRIN. One mechanism is the generation of exosomes
from multivesicular bodies undergoing exocytosis that include
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FIGURE 9 | Cell–cell contact is not required for induction of MMP-9 and
VEGF. 2 × 105 A498 or MCF-7 cells or 1 × 105 U937 cells were incubated
with TNFα (1 ng/ml) for 48h, separately, in a mixed co-culture where cell–cell
contact was allowed, or in inserts with a small pore size (0.3μm) that
precluded cell migration and cell–cell contact. Concentrations of (A) MMP-9
and (B) VEGF were determined by ELISA (n = 8).
EMMPRIN (Keller et al., 2009). Another possibility is the secre-
tion of EMMPRIN in microvesicles that are shed off from the
surface, particularly from lipid rafts (Millimaggi et al., 2007). This
microvesicle-associated EMMPRIN could enhance MMPs pro-
duction in endothelial cells, as well as increase their migration
and ability to form tube-like structures (Millimaggi et al., 2007).
A third mechanism for the secretion of EMMPRIN suggests that
the surface protein is cleaved by a protease. In fact, MT1-MMP
was found to cleave EMMPRIN in the linker region connecting
the two Ig-like domains, leading to a reduced ability of the sur-
face protein, but not the secreted protein, to induce MMPs in
fibroblasts (Egawa et al., 2006). Our results rule out the possibil-
ity of alternative splicing yielding a soluble EMMPRIN protein,
as well as the formation of relatively large structures such as
microvesicles or exosomes that carry EMMPRIN, as EMMPRIN
was not found in the pellets after ultracentrifugation. Our use
of a wide range of protease inhibitors ruled out the involve-
ment of most proteases. Specifically, the use of phenanthroline
which inhibits zinc metalloproteinases such as MT1-MMP, sug-
gested that MMPS may not be involved in the proteolytic cleav-
age of EMMPRIN. In contrast, we found that aprotinin, which
inhibits several serine proteases, could decrease the accumula-
tion of EMMPRIN in the supernatants, indicating that a serine
protease that is yet to be identified is responsible for a shedding
off of surface EMMPRIN in our system. The identification of the
specific serine protease awaits further investigation, and plasmin
or kalikrein, which are inhibited by aprotinin, seem like good
candidates.
We also demonstrate that soluble EMMPRIN, whether syn-
thetic (recombinant EMMPRIN) or produced in our co-culture
system, was able to induce both MMP-9 and VEGF from the
U937 monocytic cells. The experiments where recombinant
EMMPRIN, supernatants derived from one cell type and added
to another cell type and cells co-cultured using 0.3μm inserts—
all proved that soluble EMMPRIN was sufficient and that it
retained its pro-angiogenic activity. Directionality of EMMPRIN
activity was disclosed in the experiments where A498- or MCF-
7-derived supernatants were added to U937 cells and demon-
strated increasedMMP-9 andVEGF secretion that was reduced by
anti-EMMPRIN. The reciprocal experiment where U937-derived
supernatants were added to the tumor cells resulted in increased
VEGF, but notMMP-9 secretion, and even this was not specific, as
anti-EMMPRIN could not inhibit this effect. It is also noteworthy
that other factors found locally in the tumor microenvironment
could induce MMP-9 and VEGF. Among these factors, hypoxia
and presence of pro-inflammatory cytokines (e.g., TNFα) can
www.frontiersin.org July 2013 | Volume 4 | Article 178 | 13
Amit-Cohen et al. Secreted EMMPRIN increases angiogenesis
FIGURE 10 | Soluble EMMPRIN has pro-angiogenic properties. 2 × 106
Eahy926 cells were grown to confluency in 24-well plates, and a wound
assay was performed by making a scratch, as described in the methods.
(A) A representative photograph of the scratched area in a wound assay
at the beginning (0 h) and at the end (48h) of the experiment
(magnification X40) while adding recombinant EMMPRIN (200ng/ml). Gray
lines depict the cell front. (B) Rate of wound closure was measured by
comparing the distance between the two sides of the scratch using
image analysis software at the beginning and at the end of the
experiment, and calculating the percent of change (n = 3). (C) A
representative photograph of scratched area in a wound assay when
adding diluted (1:4) supernatants derived from the co-cultures or
co-cultures where A498 cells were first transfected with EMMPRIN
siRNA or its negative control (NC), and (D) analysis of its rate of wound
closure (n = 3). (E) Matrigel plug assay was carried out as described in
the methods, and plugs were removed and photographed after 7 days.
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induce VEGF and MMP-9 through the activity of the HIF and
NF-κB transcription factors (Pages and Pouyssegur, 2005; Yan
and Boyd, 2007). EMMPRIN is not redundant, however, and it
has a role in maximizing secretion of VEGF and MMP-9, as we
show by specifically targeting EMMPRIN, either by siRNA or by
anti-EMMPRIN.
Thus, increased tumoral EMMPRIN expression results in gen-
eration of soluble EMMPRIN, which probably binds to its ligand
on monocytes (either a yet unknown ligand, or EMMPRIN
itself through homophilic interactions), and induces secretion
of MMP-9 and VEGF from monocytes. This is also in agree-
ment with the fact that monocytes and macrophages are better
producers of these proteins than tumor cells.
Finally, EMMPRIN pro-angiogenic activity is not limited to
induction of MMP-9 and VEGF. Recent studies have shown
that EMMPRIN may directly contribute to the regulation of the
angiogenic process by up-regulating soluble forms of VEGF and
VEGFR2 in endothelial cells (Bougaten et al., 2009; Pinheiro
et al., 2012). We therefore examined the effects of EMMPRIN
on endothelial cells in vitro using the wound assay. We show that
recombinant EMMPRIN could accelerate the rate of wound clo-
sure, and when EMMPRIN expression in tumor cells was silenced
by siRNA, wound repair was inhibited. Likewise, addition of
EMMPRIN to matrigel plugs resulted in growth of blood ves-
sels into the plug, demonstrating that EMMPRIN directly affects
endothelial cells in vivo as well. Thus, EMMPRIN is directly
involved in endothelial migration/proliferation, and the mech-
anisms that are responsible for this action should be further
explored.
In conclusion, we show that co-cultures of tumor cells and
macrophages induce EMMPIN expression, as well as produc-
tion of MMP-9 and VEGF, mostly by the macrophages. Secreted
EMMPRIN, which is generated in our system by a serine protease
that is yet to be identified, is functional and sufficient to stimu-
late macrophages to produce VEGF and MMP-9. Furthermore,
EMMPRIN has an additional direct pro-angiogenic effect on
endothelial cells, suggesting that in the tumoral microenviron-
ment angiogenesis is orchestrated by the effects of EMMPRIN
in this triage of tumor cell-macrophage-endothelial cell inter-
actions, and emphasizing the importance of such interactions.
Additional questions, such as the deciphering of the signal-
ing pathway that is responsible for the increased EMMPRIN
expression and enhanced miR-146a expression merit further
investigation.
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